PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate ...
Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents. Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an investigational treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback